AI-powered
podcast player
Listen to all your favourite podcasts with AI-powered features
2min chapter
#396 Recap, Top Pearls from #SGIM23
The Curbsiders Internal Medicine Podcast
The Clarity AD Trial
The Clarity AD trial evaluated the new monoclonal antibody, Lacanamab. It is great at reducing soluble amyloid. The bad news is that clinically, the reduction in function does not mitigate that much. But there were some pretty significant adverse events, including the death.
00:00
Transcript
Episode notes
Get the Snipd
podcast app
Unlock the knowledge in podcasts with the podcast player of the future.
AI-powered
Discover
highlights
Listen to the best highlights from the podcasts you love and dive into the full episode
Save any
moment
Hear something you like? Tap your headphones to save it with AI-generated key takeaways
Share
& Export
Send highlights to Twitter, WhatsApp or export them to Notion, Readwise & more
AI-powered
podcast player
Listen to all your favourite podcasts with AI-powered features
Discover
highlights
Listen to the best highlights from the podcasts you love and dive into the full episode